--- title: "FDA-Approved Weight-Loss Pills in 2026" description: "Compare FDA-approved weight-loss pills in 2026: daily routines, key safety differences, trial evidence and questions to ask before choosing treatment." summary: "FDA-approved pills for long-term weight management include orlistat, Qsymia, Contrave, Wegovy tablets and Foundayo. They differ in how they work, how you take them and who can use them. Compounded oral semaglutide does not share those product approvals." canonical: https://remevihealth.com/blog/fda-approved-weight-loss-pills/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "Linda West-Conforti, RN" reviewStatus: current reviewedDate: 2026-09-22T00:00:00.000Z pubDate: 2026-06-05T00:00:00.000Z updatedDate: 2026-09-17T00:00:00.000Z tags: ["fda approved weight loss pills","weight loss pills","prescription weight loss medication","pills vs injections"] alternateLanguage: https://remevihealth.com/es/blog/pastillas-para-bajar-de-peso-fda/ license: "© 2026 REMEVi LLC. Please cite https://remevihealth.com/blog/fda-approved-weight-loss-pills/ as the source." --- ## Short answer FDA-approved pills for long-term weight management include orlistat, Qsymia, Contrave, Wegovy tablets and Foundayo. They differ in how they work, how you take them and who can use them. Compounded oral semaglutide does not share those product approvals. **Medically reviewed by** [Linda West-Conforti, RN](/medical-team/) · [CA RN #389453](https://search.dca.ca.gov/details/4500/RN/389453/) · 2026-09-22. Founding Nurse · Patient Care Lead. ## Which weight-loss pills are FDA-approved? The most useful starting point is the **exact medicine and formulation**. A familiar ingredient name does not tell you whether a product is approved for weight management. This guide focuses on adult oral options; pediatric use and other indications need their own assessment. | Oral option | How it works | A practical difference | | --- | --- | --- | | Orlistat: Xenical / alli | Reduces absorption of some dietary fat in the gut. | Meal-linked use; oily stools and urgency can affect your routine. Lower-dose alli is available without a prescription for eligible adults. | | Qsymia: phentermine/topiramate extended release | Combines medicines with appetite-related effects. | Requires pregnancy precautions and a review of mood, cognition and other risks. | | Contrave: naltrexone/bupropion extended release | Acts on pathways involved in appetite and food reward. | Opioid use, seizure history and blood pressure are important screening questions. | | Wegovy tablets: semaglutide | Activates GLP-1 receptors involved in appetite regulation. | Has specific fasting and water instructions. | | Foundayo: orforglipron | An oral GLP-1 receptor agonist. | Can be taken with or without food; it has its own interaction and safety requirements. | These are long-term weight-management options used alongside nutrition and physical activity. The table is a starting comparison, not a complete safety checklist. Sources: [NIDDK medication overview](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity), [Qsymia prescribing information](https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf?v=0924), [Contrave prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b), [Wegovy prescribing information](https://www.novo-pi.com/wegovy.pdf), [Foundayo prescribing information](https://pi.lilly.com/us/foundayo-uspi.pdf). **Phentermine alone is different from Qsymia.** Its approval is for short-term use, described in its label as a few weeks. Do not assume a combination medicine's long-term indication applies to a single ingredient. [Adipex-P prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf6e2aa5-e8e1-4478-93b9-47632a924482&version=22) ## Wegovy and Foundayo: two oral GLP-1 options FDA approved Foundayo on **April 1, 2026**, for weight reduction and long-term maintenance in adults with obesity, or overweight with a weight-related condition. Describing Wegovy as the only approved oral GLP-1 option for obesity is now out of date. [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program) The daily routine can help frame a discussion. Wegovy tablets are taken in the morning on an empty stomach with up to four ounces of water, followed by at least 30 minutes before food, drinks or other oral medicines. Foundayo may be taken with or without food. Neither schedule is an instruction for a compounded oral preparation. [Wegovy label, section 2.1](https://www.novo-pi.com/wegovy.pdf) · [Foundayo label, section 2](https://pi.lilly.com/us/foundayo-uspi.pdf) For example, if you take other morning medicines or work changing shifts, bring that routine to the appointment. Ask how the proposed medicine would fit it. Our [Foundayo versus Wegovy pill guide](/blog/foundayo-vs-wegovy-pills/) explores that choice in more detail. The same number of milligrams does not mean an equivalent dose across different products or routes. Do not convert oral and injectable doses yourself; switching requires the prescriber's product-specific instructions. [Wegovy label, section 2.5](https://www.novo-pi.com/wegovy.pdf) ## What do the weight-loss studies actually tell us? **OASIS 4** randomized 307 adults with obesity, or overweight with a related condition, without diabetes. With lifestyle support, oral semaglutide 25 mg produced an estimated average weight change of **−13.6% at 64 weeks**, versus **−2.2% with placebo**, in the published treatment-policy analysis. These are group averages; participants had differing responses and some stopped treatment. [OASIS 4 primary publication](https://doi.org/10.1056/NEJMoa2500969) Keep the analysis attached to the number: the current Wegovy label's Study 7 table reports a **−2.4% placebo change** with its specified analysis, while the publication above reports −2.2%. Do not combine figures from different analyses. OASIS 1 studied **50 mg oral semaglutide**, a different dose from the approved 25 mg Wegovy tablet maintenance dose. [Wegovy label, section 14.2](https://www.novo-pi.com/wegovy.pdf) · [OASIS 1 primary publication](https://pubmed.ncbi.nlm.nih.gov/37385278/) Foundayo's label describes a separate 72-week trial in adults without diabetes: the highest approved dose group averaged **−11.1%**, versus **−2.1% with placebo**, in the intent-to-treat analysis. This is not a head-to-head comparison with Wegovy. Different populations, protocols and handling of missing data limit comparisons across trials. [Foundayo label, Table 6](https://pi.lilly.com/us/foundayo-uspi.pdf) **None of these results establish outcomes for REMEVi's finished compounded preparations.** For the wider treatment context, see [how to interpret a weight-loss timeline](/blog/weight-loss-results-timeline/). ## Safety questions that can change the choice Your clinician needs a complete medicine list, including supplements, plus your diagnoses and pregnancy plans. Risks differ by product: - **Qsymia:** pregnancy is a contraindication because of fetal harm. Ask about pregnancy testing, contraception, eye symptoms, mood changes and how to stop safely; abrupt withdrawal of higher doses can cause seizures. [Qsymia label](https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf?v=0924) - **Contrave:** chronic opioid use, uncontrolled high blood pressure and seizure disorders are among its contraindications. It also carries a boxed warning about suicidal thoughts and behaviors associated with antidepressants. [Contrave label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b) - **Orlistat:** discuss digestive effects, medicine interactions and vitamin needs. FDA updated alli warnings in June 2026 concerning kidney stones and kidney injury. [FDA safety communication](https://www.fda.gov/drugs/drug-safety-communications/fda-approves-labeling-changes-over-counter-otc-weight-loss-drug-alli-orlistat-warn-risk-kidney) - **Oral GLP-1 products:** both labels include thyroid C-cell tumor warnings and contraindications for personal or family medullary thyroid carcinoma or MEN 2. Gastrointestinal symptoms, dehydration and other risks need review. [Wegovy label](https://www.novo-pi.com/wegovy.pdf) · [Foundayo label](https://pi.lilly.com/us/foundayo-uspi.pdf) Get urgent medical help for severe persistent abdominal pain or inability to keep fluids down. Trouble breathing or swelling of the face or throat requires emergency care. Ask your prescriber which symptoms should mean stopping your specific medicine and calling immediately. The product labels above explain their individual warning signs. ## Approved, compounded and supplement are different categories FDA approval applies to a specific finished product. A compounded oral preparation is not Wegovy, Ozempic or Rybelsus, and is not an FDA-approved generic. FDA does not review compounded medicines for safety, effectiveness and quality before marketing. They should only be used when an approved medicine cannot meet the patient's medical needs. [FDA on unapproved GLP-1 medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) Dietary supplements are another category. They do not undergo FDA premarket approval for safety and effectiveness. A “natural” label does not make a supplement an approved obesity medicine. [FDA: dietary supplements](https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements) REMEVi's [oral semaglutide page](/oral-semaglutide/) describes its compounded offering. Read that formulation's disclosures alongside the [pharmacy information](/pharmacies/), rather than using branded tablet trial results as a prediction. ## Bring these questions to your clinician 1. Which exact product and approved indication are we discussing? 2. What in my history or medicine list makes it suitable—or unsuitable? 3. How will I take it on a normal workday, and what should I do after a missed dose? 4. How will we assess nutrition, tolerability and response, and when would we change the plan? 5. What is the complete cost over the same treatment period, including visits and follow-up? 6. If a compounded medicine is proposed, what medical need cannot be met by an approved option? Compare actual coverage and pharmacy costs for approved products. For REMEVi's program, the [pricing page](/pricing/) lists the 24-week offer, full prepaid charges and shorter options. A lower four-week equivalent is not the same as a smaller payment due today. ## Frequently asked questions ### Is Wegovy the only GLP-1 pill for obesity? No. FDA approved Foundayo (orforglipron) on April 1, 2026. Both have adult weight-management indications, but their formulations, instructions and other approved uses differ. ### Can I get an approved weight-loss pill without a prescription? Lower-dose orlistat, sold as alli, is an over-the-counter option for adults who meet its label criteria. Other medicines discussed here require a prescription. Over-the-counter availability does not remove risks or interactions. ### Is compounded oral semaglutide equivalent to an approved tablet? No. A compounded preparation is not an FDA-approved generic of Wegovy, Ozempic or Rybelsus. Sharing an ingredient does not establish the same absorption, effectiveness or safety. ### Are pills safer than injections? The route alone does not establish safety. Each medicine has its own risks, interactions and administration instructions. Your health history and the exact product matter more than whether it is swallowed or injected. ### Which pill is best for me? There is no single best pill for everyone. Discuss the approved indication, medical history, medicines you already take, daily routine, coverage, full cost and follow-up with a licensed clinician. ## Sources linked in this article These are the external references linked in the article. A reference supports the statement where it appears; it is not an endorsement of REMEVi or a substitute for individual medical advice. - [NIDDK medication overview](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) - [Qsymia prescribing information](https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf?v=0924) - [Contrave prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b) - [Wegovy prescribing information](https://www.novo-pi.com/wegovy.pdf) - [Foundayo prescribing information](https://pi.lilly.com/us/foundayo-uspi.pdf) - [Adipex-P prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf6e2aa5-e8e1-4478-93b9-47632a924482&version=22) - [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program) - [OASIS 4 primary publication](https://doi.org/10.1056/NEJMoa2500969) - [OASIS 1 primary publication](https://pubmed.ncbi.nlm.nih.gov/37385278/) - [FDA safety communication](https://www.fda.gov/drugs/drug-safety-communications/fda-approves-labeling-changes-over-counter-otc-weight-loss-drug-alli-orlistat-warn-risk-kidney) - [FDA on unapproved GLP-1 medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [FDA: dietary supplements](https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements) ## Related reading - [Rybelsus vs Ozempic: Pill vs Injection](/blog/rybelsus-vs-ozempic/) - [Weight-Loss Pills vs Injections: Which?](/blog/weight-loss-pills-vs-injections/) ## About this article Published by REMEVi, a telehealth business offering paid treatment programs. REMEVi has a commercial interest in the services discussed here. Educational content supports informed conversations with a licensed clinician; it does not determine your eligibility or replace individual care.